(TheNewswire)
VANCOUVER, BC – TheNewswire- February 15, 2023 - AREV LIFE SCIENCES GLOBALCORP. (CSE:AREV) (OTC:AREVF) (“AREV” or the “Company”) AREV Life Sciences GlobalCorporation is pleased to announce it has commenced research to identify advanced isolationtechnology for its proprietary extract after learning results of a newstudy on Hericium erinaceus extract from Lions Mane.
Using super-resolution microscopy, the team from TheQueensland Brain Institute - University of Queensland found theextract from Lions Mane Mushroom and its active components largelyincrease the size of growth cones, which are particularly importantfor brain cells to sense their environment and establish newconnections with other neurons in the brain. N-de phenylethylisohericerin (NDPIH), an isoindoline compound from this mushroom,together with its hydrophobic derivative hericene A, were highlypotent in promoting extensive axon outgrowth and neurite branching incultured hippocampal neurons even in the absence of serum,demonstrating potent neurotrophic activity.
The discovery has applications that could treat and protect againstneurodegenerative cognitive disorders such as Alzheimer’s disease.Active compounds in the edible Lion’s Mane mushroom can help promoteneurogenesis and enhance memory, the new study reports. Preclinicaltrials report the compound had a significant impact on neural growthand improved memory formation. Researchers say the compound could haveclinical applications in treating and preventing neurodegenerativedisorders such as Alzheimer’s disease.
This new study was published in the Journal ofNeurochemistry https://onlinelibrary.wiley.com/doi/10.1111/jnc.15767 .
Arev’s Scientific Advisory Board Member Dr.Sateesh Apte, who specializes in neurology and has an extensivebackground in research, teaching and consulting in the field ofneurological sciences stated… “This is a very exciting finding.The neuroscience community is always trying to find pharmacologicallyactive ingredients that would increase neuroplasticity in aging anddegenerative conditions. Active ingredients such as NDPIH andErinacene A, have shown remarkable promise in studies done in KULeuven in Belgium and in Chung Shang University in Taiwan. It has beendemonstrated that these compounds work much better in early stages ofaging and neurodegeneration.”
In another study published in Molecules, theauthors note, Ericenones could promote thesecretion of nerve growth factor (NGF) in a rat adrenal medullapheochoursomocytoma cell line (PC12). The erinacines were primarilyseparated from the Hericium mycelium fermented liquid, includingerinacines A-K and erinacines P-R, and also had an effect in promotingthe expression of NGF and the differentiation of axons in PC12 cells.Erinacines could induce relatively more NGF secretion than ericenones. The aqueous polysaccharide extract of Hericium erinaceus couldpromote peripheral nerve regeneration after a nerve injury crush inrats. The crude extracts of Hericium erinaceus mycelium inhibitpurinoceptors to relieve neuropathic pain and neuro - in?amation in mice. (Source Molecules 2021, 26, 3297. https://doi.org/10.3390/molecules26113297 )
This is an important discovery that supportst he methods and technology AREV hasdeveloped. AREV continuesto build on its core competency of extraction and formulation . Arev has successfully extracted 10% Hericenones using amodified method of its existing extraction technology. The 10% yieldis exceptional, according to the expert mycologists working Arev’sLions Mane extraction. With news of thediscovery, t he remaining 90% ofthe Arev extract which contains unidentifiedcompounds that demonstrate polysaccharidecharacteristics need s to be isolated and identified. This requires additional processing with thea bility to fractionalize our extracts for medical andpharmaceutical compounding to treat specific diagnosis’ and matchcustom oil blends to a patient’s DNA sequencing thereby providingthe optimal medical result available in the market.
The company will now evaluat e 3rdparty isolation systems to separate targeted molecules from its LionsMane extract and the other extracts frommaterials such as Full Spectrum Cannabis/Hemp Oil, Cinnamon,Frankinsence, Hops, and Moringa that Arev has also been workingwith . Ideally, the newtechnology will p rovide the versatility ofcompounding isolates for accurate micro-dosing which is ideal forpharmaceutical , bioceutical and nutraceutical applications.
Each “refinement” is being designed as a standard operating procedure “SOP” for the specific extraction of the natural substance that can ultimately be used as an active compound for an intended intervention to the particular healthcondition of the patient population .
For further information, contact Mike Withrow,arevlifesciences@gmail.com 778-929-6536. For more information visitwww.arevlifesciences.com.
On behalf of the Board,
Mike Withrow
CEO & Director
About AREV Life Sciences GlobalCorp.
The Company is a fully integrated enterprise withcompetencies in: 1) extraction of compounds for consumption andtopical use. 2) Clinical Nutrition and 3) A technology platform calledMedicine Merchant. The Company produces ingredients and formulatesexclusive therapeutic interventions with plans to deliver innovationin clinical nutrition, proprietary supplements, topicals and rationaldrug design, based on science. The Company’s business modelleverages its core competency of extraction to produce ingredients andcompounds for its pipeline of products. The Company continues in theproduct development and pre-commercialization stage.
AREV is dedicated to designing and deliveringinnovation in rational drug design, driven by presenting globalepidemiological characteristics of multiple challenges tointernational human and animal health. AREV is a member of bothBIOTECanada and The Biotechnology Innovation Organization (BIO).
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITSREGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITYFOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Neither the Canadian Securities Exchange nor itsRegulation Services Provider (as that term is defined in policies ofthe CSE) accepts responsibility for the adequacy or accuracy of thisrelease. This news release may include forward-looking statements thatare subject to risks and uncertainties. All statements within, otherthan statements of historical fact, are to be considered forwardlooking. Although the Company believes the expectations expressed insuch forward looking statements are based on reasonable assumptions,such statements are not guarantees of future performance and actualresults or developments may differ materially from those inforward-looking statements. Factors that could cause actual results todiffer materially from those in forward-looking statements includemarket prices, exploitation and exploration successes, and continuedavailability of capital and financing, and general economic, market orbusiness conditions. There can be no assurances that such statementswill prove accurate and, therefore, readers are advised to rely ontheir own evaluation of such uncertainties. We do not assume anyobligation to update any forward-looking statements except as required
under the applicable laws. This press release containsforward-looking statements. The use of any of the words"anticipate", "continue", "estimate","expect", "may", "will","project", "should", "believe" andsimilar expressions are intended to identify forward-lookingstatements. Although the Company believes that the expectations andassumptions on which the forward-looking statements are based arereasonable, undue reliance should not be placed on the forward-lookingstatements because the Company can give no assurance that they willprove to be correct. Since forward-looking statements
address future events and conditions, by their verynature they involve inherent risks and uncertainties. These statementsspeak only as of the date of this press release. Actual results coulddiffer materially from those currently anticipated due to a number offactors and risks various risk factors discussed in theCompany’ s Management ’sDiscussion and Analysis under the Company’s profile on www.sedar.com.
Copyright (c) 2023 TheNewswire - All rights reserved.